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Summary Thirty patients with previously treated metastatic breast cancer were entered in a phase II study
with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission
was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progressed (40%). Toxicity
was acceptable, consisting mainly of myalgias (39% of patients) and asthenia (21.4%). No myelotoxicity was
observed. The drug is active in previously treated metastatic breast cancer and, because of its peculiar pattern
of action and toxicity, deserves to be evaluated in combination with cytotoxic chemotherapy.
The indazole carboxylic acids can produce severe
mitochondrial alterations, inhibition of oxygen consumption
and of aerobic glycolysis (Floridi et al., 1981).
Lonidamine [1(2, 4 - dichlorobenzyl) - 1 - H - imidazole
carboxylic acid] was the first of these compounds to be
studied for its antispermatogenic properties. During the
preclinical phase of development, the drug exhibited an
antitumour activity, being able to increase the life span of
mice previously inoculated with Lewis lung carcinoma and
sarcoma 180 (Silvestrini, 1981).
The toxicity of lonidamine in animal models consisted of
lesions of the seminiferous epithelium in rat (the most
sensitive animal), rabbit, dog and monkey (De Martino et
al., 1981). At high doses lonidamine was nephrotoxic in the
monkey (Heywood et al., 1981).
The pharmacokinetics of lonidamine were highly variable.
The half-life evaluated from the beta phase for plasma levels
was 14.8 h + 12.7 h (mean + s.d. for seven patients treated
with 300mg tablets) (Besner et al., 1984; Weinerman et al.,
1986). In man, myalgia was the dose limiting toxicity; it
appeared at the dose of 300-400mgm-2 and was relieved
by hydrocortisone but not by aspirin or morphine (Band et
al., 1984). The mechanism of action of hydrocortisone in
relieving myalgia is not yet known. Other toxicities were
somnolence, hyperaestesia, mild hair loss and testicular pain.
Less common toxicities were gastrointestinal symptoms
(mainly diarrhoea and meteorism), chills and fever,
headache, articular pain, altered hearing and conjunctivitis.
All side effects rapidly disappeared after stopping the
treatment. Neither myelosuppression nor laboratory
abnormalities were observed. This pattern of toxicity was
confirmed in other trials (Weinerman et al., 1986; Band et
al., 1986).
The present phase II study was undertaken to evaluate the
activity and toxicity of lonidamine in metastatic breast
cancer patients.
Materials and methods
Thirty patients with metastatic breast cancer were entered in
the study and treated with oral lonidamine. Criteria for entry
included histologically or cytologically confirmed metastatic
breast cancer which had become unresponsive to standard
treatment, the presence of measurable or evaluable disease, a
performance status <2 (ECOG scale), normal hepatic, renal
and cardiac function, recovery from the effects of previous
treatments (white blood cell count > 3,500 mm
haemoglobin > 10 gdl-1 platelets > 100,000 mm-3); a
verbal informed consent was required.
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Baseline investigations included a complete physical
examination and laboratory assessment. Chest X-rays, bone
scintiscans and liver ecotomograms were performed as
clinically indicated to document metastatic disease and to
evaluate response to lonidamine.
Response and toxicity were assessed according to the rules
of WHO/UICC (Miller et al., 1981): a complete response is
defined as disappearance of all known disease for at least 4
weeks; a partial response is defined for bidimensional disease
as a decrease equal to or greater than 50% of the product of
the two greatest perpendicular diameters of measurable
lesions for at least 4 weeks and for unidimensional disease as
a decrease equal to or greater than 50% of the lesions for at
least 4 weeks; a stable disease is defined for bidimensional
lesions as less than a 25% increase or less than a 50%
decrease in the size of one or more measurable lesions for at
least 4 weeks; progression of the disease is defined for
bidimensional lesions as an increase greater than 25% of the
product of the longest perpendicular diameters of measured
lesions or appearance of new lesions.
For bone metastases, complete response consists of
complete disappearance of all lesions on X-ray or scan for at
least 4 weeks; partial response is defined as a decrease or
recalcification of lytic lesions for at least 4 weeks; stable
disease is applied when at least 8 weeks have passed from
start of therapy without signs of response or progression;
progressive disease is defined as increase in size of existent
lesions or appearance of new lesions.
Time to response is evaluated from the first day of
treatment to the first evidence of response. The duration of
response is measured from the beginning of therapy to the
date of disease progression. Patients are considered evaluable
for toxicity from the start of treatment.
Lonidamine was supplied by Angelini Research Institute,
Rome, Italy, as 150mg tablets and given orally at a daily
dose of 225mg (in three divided doses) from day 1 to day 3,
at a daily dose of 450mg (in three divided doses) from day 4
to day 7, and then at the daily dose of 600mg (in three
divided doses) from day 8 onwards. The drug was
administered for a minimum of 8 weeks unless disease
progression occurred or severe toxicity prevented the
continuation of drug administration.
Patients reporting grade IV toxicity were considered off
study, while in those patients with grade III or II toxicity the
dose was reduced to the previous dose level, until recovery
of toxicity to grade I, after which the dose was increased
again to 600mgday-1. Prednisone was not administered.
Results
Among 30 patients entered in the study, 28 were evaluable
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for toxicity and 25 for response. Two patients were not
evaluable for toxicity or for response because they were lost
before the first follow-up. Three patients experienced grade
III myalgia, and refused further treatment at decreased
dosage; they were not considered evaluable for response
since they did not receive adequate treatment. No other
patient discontinued treatment because of toxicity.
Patients' characteristics are summarised in Table I. The
median treatment duration for all evaluable patients was 8
weeks (range 4-32+ weeks).
We observed no complete responses, four partial responses
(16%, with 95% confidence limits of 4-37%), 11
stabilisations (44%) and 10 progressions (40%). The median
time to response was 4 weeks (range 2-4 weeks): the median
duration of response was 18 weeks (range 12-30 weeks).
Responding patients' characteristics are summarised in Table
II. Seventeen patients (including the four responding
patients) received full doses of lonidamine, while eight
decreased the dosage to 450mg because of toxicity, which
did not permit recovery of the full dosage of the drug.
Toxicity was recorded as the worst grade for each patient.
No grade IV toxicity was reported. We observed myalgia in
11 patients (39%: grade I in four patients, grade II in four,
grade III in three); asthenia in six patients (21.4%: grade I in
three and grade II in three); dry cough in five (18%),
abdominal cramps in two (7%), nausea, anorexia,
constipation and arthralgia in one patient each (4%). Side-
effects tended to decrease after a few weeks of therapy. We
did not observe any haematological, hepatic or renal toxicity
and no patient reported a hearing loss or other signs of
ototoxicity.
Discussion
In this phase II study of the new drug lonidamine, we have
observed four partial responses among 25 evaluable patients
(16%). A similar response rate was observed by Band et al.
(1986): five (17%) partial responses among 30 evaluable
patients. In both studies virtually all patients treated were
postmenopausal.
Toxicity of lonidamine in women consists mainly of
myalgia and asthenia, which may be severe, but which is of
short duration and fully reversible if the dose is reduced. In
other studies prednisone was successfully employed to relieve
myalgias (Band et al., 1984). Interestingly, our study has
confirmed that lonidamine is devoid of any myelotoxic
effect.
Since lonidamine seems to have some effect in heavily
pretreated breast cancer patients, with a response rate
comparable to that of other single agents, a further accrual
of less pretreated patients could be useful in defining the
drug activity and identifying subsets of patients more likely
to respond. However, results of lonidamine phase II trials in
breast cancer and other malignancies (Evans et al., 1984;
Barduagni et al., 1984; Kokron et al., 1984) are of interest
mainly because of the unique mode of action and toxicity of




Evaluable for toxicity 28
Evaluable for response 25
Median age (years) 60 (42-78)
Median disease free interval (months) 18 (0-35)
Postmenopause 30
Median PS (ECOG) 0 (0-2)







Adjuvant hormone therapy 2
Chemotherapy for metastases 3
Hormone therapy for metastases 7
Chemotherapy and hormone therapy for metastases 20
Table II Responding patients' characteristics
Patient Age PS Metastases CT HT TTR DoR Lnd dose
D.M.C. 51 0 bone, s.t. y y 4 12 600
B.M. 76 0 lung, s.t. y y 4 24 600
G.P. 79 0 s.t. n y 4 12 600
P.L. 62 0 s.t. y y 2 30 600
PS, performance status (ECOG); s.t., soft tissues; CT, previous
chemotherapy for metastases; HT, previous hormone therapy for
metastases; TTR, time to response (weeks); DoR, duration of
response (weeks); Lnd dose, daily dose of lonidamine (mg); y, yes; n,
no.
the drug, which suggest the potential for combination with
radiotherapy (Hahn et al., 1984; Magno et al., 1984),
hyperthermia (Silvestrini et al., 1983; Chitnis & Adwankar,
1986) and chemotherapy (Pacilio et al., 1984; Battelli et al.,
1984). Until now, few controlled clinical trials of the
combination of lonidamine with chemotherapy have been
carried out in non-small cell lung cancer (Breau et al., 1988;
Gallo Curcio et al., 1987), malignant glioma (Carapella et
al., 1988) and bladder carcinoma (Giannotti et al., 1984).
Preliminary data show that lonidamine does not potentiate
the toxic effects of chemotherapy, while conclusions on
effectiveness cannot be drawn yet.
No published data are available on the combination of
lonidamine and chemotherapy concerning breast cancer.
Since phase II trials have shown the activity of this agent in
breast cancer patients and preclinical data suggest a
synergism of lonidamine with doxorubicin (the most effective
single agent in breast cancer) (Zupi et al., 1986; Bagnato et
al., 1987), the combination of lonidamine and doxorubicin-
containing schedules deserves to be studied.
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